دورية أكاديمية
Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study.
| العنوان: | Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study. |
|---|---|
| المؤلفون: | Buis DTP; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands., van der Vaart TW; Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, the Netherlands., Prins JM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands., van der Meer JTM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, the Netherlands., Bonten MJM; Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands., Sieswerda E; Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands., van Werkhoven CH; Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands., Sigaloff KCE; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands., Herpers BL; Regional Public Health Laboratory Kennemerland, Haarlem, The Netherlands., Jansen RR; Department of Medical Microbiology, OLVG, Amsterdam, The Netherlands., Rozemeijer W; Department of Medical Microbiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Soetekouw R; Department of Internal Medicine, Spaarne Gasthuis, Haarlem, The Netherlands., van Twillert G; Department of Internal Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Veenstra J; Department of Internal Medicine, OLVG, Amsterdam, The Netherlands. |
| المصدر: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2023 May 03; Vol. 78 (5), pp. 1175-1181. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1997- : London : Oxford University Press Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | Bacteremia*/epidemiology , Staphylococcal Infections*/epidemiology, Adult ; Humans ; Staphylococcus aureus ; Methicillin/therapeutic use ; beta-Lactams/therapeutic use ; Cefuroxime/therapeutic use ; Floxacillin/therapeutic use ; Ceftriaxone/therapeutic use ; Prospective Studies ; Anti-Bacterial Agents/therapeutic use |
| مستخلص: | Objectives: Standard once-daily dosing of ceftriaxone may not lead to adequate antibiotic exposure in all cases of Staphylococcus aureus bacteraemia (SAB). Therefore, we compared clinical effectiveness of empirical antibiotic treatment with flucloxacillin, cefuroxime and ceftriaxone in adult patients with MSSA bacteraemia. Methods: We analysed data from the Improved Diagnostic Strategies in Staphylococcus aureus bacteraemia (IDISA) study, a multicentre prospective cohort study of adult patients with MSSA bacteraemia. Duration of bacteraemia and 30 day SAB-related mortality were compared between the three groups using multivariable mixed-effects Cox regression analyses. Results: In total, 268 patients with MSSA bacteraemia were included in the analyses. Median duration of empirical antibiotic therapy was 3 (IQR 2-3) days in the total study population. Median duration of bacteraemia was 1.0 (IQR 1.0-3.0) day in the flucloxacillin, cefuroxime and ceftriaxone groups. In multivariable analyses, neither ceftriaxone nor cefuroxime was associated with increased duration of bacteraemia compared with flucloxacillin (HR 1.08, 95% CI 0.73-1.60 and HR 1.22, 95% CI 0.88-1.71). In multivariable analysis, neither cefuroxime nor ceftriaxone was associated with higher 30 day SAB-related mortality compared with flucloxacillin [subdistribution HR (sHR) 1.37, 95% CI 0.42-4.52 and sHR 1.93, 95% CI 0.67-5.60]. Conclusions: In this study, we could not demonstrate a difference in duration of bacteraemia and 30 day SAB-related mortality between patients with SAB empirically treated with flucloxacillin, cefuroxime or ceftriaxone. Since sample size was limited, it is possible the study was underpowered to find a clinically relevant effect. (© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.) |
| التعليقات: | Erratum in: J Antimicrob Chemother. 2023 May 23;:. (PMID: 37221129) Erratum in: J Antimicrob Chemother. 2023 Dec 11;:. (PMID: 38078830) |
| References: | Int J Antimicrob Agents. 2022 Jan;59(1):106486. (PMID: 34839007) Open Forum Infect Dis. 2018 May 18;5(5):ofy089. (PMID: 30568987) Ann Intern Med. 2002 Nov 19;137(10):791-7. (PMID: 12435215) Clin Infect Dis. 2022 Apr 28;74(8):1442-1449. (PMID: 34272564) J Antimicrob Chemother. 2018 Jun 1;73(6):1620-1629. (PMID: 29522167) Crit Care Med. 2003 Apr;31(4):1250-6. (PMID: 12682500) Clin Microbiol Infect. 2011 Oct;17(10):1581-6. (PMID: 21073629) J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716) Clin Infect Dis. 2000 Apr;30(4):633-8. (PMID: 10770721) Clin Microbiol Rev. 2012 Apr;25(2):362-86. (PMID: 22491776) Open Forum Infect Dis. 2022 Nov 30;9(12):ofac653. (PMID: 36589483) J Antimicrob Chemother. 2022 Jul 28;77(8):2288-2295. (PMID: 35552420) PLoS One. 2019 Jan 2;14(1):e0208819. (PMID: 30601829) BMC Infect Dis. 2022 Aug 11;22(1):687. (PMID: 35953772) J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. (PMID: 29635472) Ann Clin Microbiol Antimicrob. 2016 Apr 26;15:27. (PMID: 27112143) Microbiol Spectr. 2022 Jun 29;10(3):e0153021. (PMID: 35438533) Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa341. (PMID: 32908944) Int J Clin Pharm. 2014 Dec;36(6):1282-9. (PMID: 25186790) J Infect. 2014 Mar;68(3):242-51. (PMID: 24247070) Lancet Infect Dis. 2020 Dec;20(12):1409-1417. (PMID: 32763194) |
| المشرفين على المادة: | Q91FH1328A (Methicillin) 0 (beta-Lactams) O1R9FJ93ED (Cefuroxime) 43B2M34G2V (Floxacillin) 75J73V1629 (Ceftriaxone) 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20230310 Date Completed: 20230504 Latest Revision: 20231211 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10154124 |
| DOI: | 10.1093/jac/dkad057 |
| PMID: | 36897327 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2091 |
|---|---|
| DOI: | 10.1093/jac/dkad057 |